%0 Journal Article
%J PharmacoEconomics
%D 2007
%T Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.
%A Cosler, Leon E
%A Eldar-Lissai, Adi
%A Culakova, Eva
%A Kuderer, Nicole M
%A Dale, David
%A Crawford, Jeffrey
%A Lyman, Gary H
%K Costs and Cost Analysis
%K Fever
%K Granulocyte Colony-Stimulating Factor
%K Hospital Mortality
%K Hospitalization
%K Humans
%K Length of Stay
%K Models, Economic
%K Monte Carlo Method
%K NEUTROPENIA
%K Patient Discharge
%K Survival Analysis
%K Time Factors
%N 4
%P 343-51
%V 25
%X The prophylactic use of granulocyte colony-stimulating factors (G-CSFs) reduces the severity and duration of neutropenia and reduces the incidence of febrile neutropenia after cancer chemotherapy. However, the use of G-CSFs, particularly filgrastim, to treat established neutropenia remains controversial. A recent meta-analysis of randomised controlled trials (RCTs) evaluating G-CSF treatment for established febrile neutropenia demonstrated a reduction in prolonged hospitalisations. Because more than one-third of patients in the analysis were hospitalised for at least 10 days, this finding has broad pharmacoeconomic and clinical significance. This analysis presents the potential cost implications of G-CSF treatment for established neutropenia among hospitalised patients.
%8 2007